LDS/Medical Tests/Miller-Dieker Syndrome, 17p13.3 Deletion, FISH

Miller-Dieker Syndrome, 17p13.3 Deletion, FISH

Miller-Dieker syndrome (MDS) is caused by deletion of chromosome 17p13.3 region involving the LIS1 gene (officially known as PAFAH1B1) associated with lissencephaly (smooth brain). Concurrent deletion of YWHAE gene in the same region increases the severity of the lissencephaly. Deletion of other intervening genes in this region contributes to the variability of the phenotype.

Miller-Dieker syndrome clinical features include severe lissencephaly, characteristic facial malformations (high forehead, bitemporal hollowing, short nose with upturned nares, small jaw, thick upper lip, and downturned vermillion border) and severe neurodevelopmental problems with poor prognosis.

A de novo deletion in chromosome 17p13.3 has been identified in approximately 80% of individuals diagnosed with MDS while the other 20% inherited the deletion as a result of a parent being a carrier of a balanced chromosomal rearrangement.

  • Confirm or establish the diagnosis of Miller-Dieker syndrome for symptomatic patients
  • Carrier test for parents or at-risk relatives of affected individual
  • Patients with isolated lissencephaly
  • Patients with subcortical band heterotopia

Presence of deletion of chromosome 17p13.3 region involving the LIS1 gene supports a diagnosis of Miller-Dieker syndrome

Absence of deletion of chromosome 17p13.3 region involving the LIS1 gene does not support a diagnosis of Miller-Dieker Syndrome

A negative cytogenetic chromosome analysis does not exclude the possibility of a small deletion below the resolution of this technology and therefore FISH or Chromosomal Microarray Analysis (CMA) should be considered if clinically indicated

A negative FISH analysis (PAC95H6 probe is commonly used) does not exclude the possibility of partial deletions of LIS1 and intragenic mutations and therefore CMA should be considered if clinically indicated

A negative CMA results does not exclude the possibility of an intragenic deletion/duplication of LIS1 and therefore molecular tests such as LIS1 targeted deletion/duplication analysis should be considered if clinically indicated

A negative sequence analysis results does not exclude the possibility of exonic or whole gene deletions/duplications of LIS1 and therefore Cytogenetic chromosome, FISH or CMA analyses should be considered if clinically indicated

Negative (17p13.3 deletion was not detected)

Cytogenetic chromosome analysis, Fluorescence in situ Hybridization (FISH), Chromosomal Microarray Analysis (CMA), LIS1 deletion/duplication analysis by quantitative Polymerase Chain Reaction (qPCR), long-range PCR, multiplex ligation-dependent probe amplification (MLPA), targeted CMA, Sequence analysis of LIS1 flanking and coding regions.

Whole blood collected in EDTA (purple top tube).

Stability

  • Ambient: 3-7 days
  • Refrigerated: 7-14 days
Brain MRI.
5-14 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Rev Neurol (Paris). 2007 May;163(5):533-47. [PMID: 17571022]
  • Am J Med Genet. 2001 Summer;106(2):119-24. [PMID: 11579431]
  • GeneReviews. Pagon RA, Adam MP, Aedinger HH, et al., editors. Seattle (WA). 1993-2015